Market research
APLI.TO Appili Therapeutics Inc
TO CAD Healthcare
Latest close
Loading market data…
Test a moving-average rule with historical data.
Market facts
- Market cap
- 1M
- P/E ratio
- Not available
- Analyst target
- 0.15
- Dividend yield
- Not available
- Beta
- -0.19
Profile
Company facts
- Exchange
- TO
- Currency
- CAD
- Sector
- Healthcare
- Industry
- Biotechnology
- ISIN
- CA03783R1073
- Market cap
- 1M
- P/E ratio
- Not available
- Analyst target
- 0.15
- Dividend yield
- Not available
- Beta
- -0.19
About
About Appili Therapeutics Inc
Appili Therapeutics Inc., a biopharmaceutical company, focuses on the acquisition and development of treatments targeting unmet needs in infectious diseases in the United States and Canada. The company offers LIKMEZ (ATI-1501), a liquid oral taste-masked reformulation of the antibiotic metronidazole to treat anaerobic bacterial and protozoal infections. It also develops ATI-1801, a topical formulation of paromomycin in a Phase III trial for the treatment of cutaneous leishmaniasis; and ATI-1701, a live-attenuated vaccine in preclinical trials for the prevention of Francisella tularensis infection. The company has a collaboration with Vitalex Biosciences to advance VXV-01, a dual-antigen vaccine targeting invasive Candida infections. Appili Therapeutics Inc. was incorporated in 2015 and is headquartered in Halifax, Canada.
Visit company websiteCommunity
Investor discussion
0 comments
Sign in to join the APLI.TO discussion.
No comments yet
Start a focused discussion about APLI.TO.